phosphonoacetic acid has been researched along with Lung Neoplasms in 14 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Variants of the Lewis lung carcinoma were selected for resistance to N-(phosphonacetyl)-L-aspartic acid (PALA) by treatment of tumor-bearing mice with repetitive subcurative doses of PALA." | 7.66 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. ( Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ, 1981) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Variants of the Lewis lung carcinoma were selected for resistance to N-(phosphonacetyl)-L-aspartic acid (PALA) by treatment of tumor-bearing mice with repetitive subcurative doses of PALA." | 3.66 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. ( Ardalan, B; Cooney, DA; Cysyk, RL; Han, N; Hankerson, JG; Harley, C; Jayaram, HN; Johnson, RK; Kensler, TW; Mutter, G; Reck, LJ, 1981) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| "Another solid tumor, Ridgway osteogenic sarcoma, which is sensitivie to many established chemotherapeutic agents, did not respond to PALA." | 1.26 | Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. ( Goldin, A; Inouye, T; Johnson, RK; Stark, GR, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (71.43) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Yin, H | 1 |
| Panandikar, A | 1 |
| Gandhi, V | 1 |
| Sen, S | 1 |
| Creech, RH | 2 |
| Tritchler, D | 2 |
| Ettinger, DS | 2 |
| Ferraro, JA | 1 |
| Ruckdeschel, JC | 1 |
| Vogl, SE | 1 |
| Woll, J | 1 |
| Monks, A | 1 |
| Anderson, LW | 1 |
| Strong, J | 1 |
| Cysyk, RL | 2 |
| Earhart, R | 1 |
| Kensler, TW | 2 |
| Mutter, G | 1 |
| Hankerson, JG | 1 |
| Reck, LJ | 2 |
| Harley, C | 1 |
| Han, N | 1 |
| Ardalan, B | 2 |
| Johnson, RK | 4 |
| Jayaram, HN | 1 |
| Cooney, DA | 2 |
| Piao, CQ | 2 |
| Hei, TK | 2 |
| Wu, LJ | 1 |
| Willey, JC | 1 |
| Hall, EJ | 1 |
| Moyer, JD | 1 |
| Handschumacher, RE | 1 |
| Swyryd, EA | 1 |
| Stark, GR | 2 |
| Inouye, T | 1 |
| Goldin, A | 1 |
| Sridhar, KS | 1 |
| Benedetto, P | 1 |
| Richman, S | 1 |
| Waldman, S | 1 |
| Morrell, L | 1 |
| Feun, L | 1 |
| Savaraj, N | 1 |
| Fodor, M | 1 |
| Livingstone, A | 1 |
| Morton, RF | 1 |
| Creagan, ET | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
4 trials available for phosphonoacetic acid and Lung Neoplasms
| Article | Year |
|---|---|
Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
Topics: Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcin | 1984 |
Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Female; Humans | 1984 |
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
10 other studies available for phosphonoacetic acid and Lung Neoplasms
| Article | Year |
|---|---|
Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Aspartic Acid; Brain Neoplasms; Cell Line, Tumo | 2015 |
Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Carbon Diox | 1983 |
Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Topics: Amides; Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carcinoma; Cell Line; Dose-Response | 1981 |
Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydr | 1981 |
Gene amplification and microsatellite instability induced in tumorigenic human bronchial epithelial cells by alpha particles and heavy ions.
Topics: Alpha Particles; Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic | 2001 |
Genomic instability and tumorigenic induction in immortalized human bronchial epithelial cells by heavy ions.
Topics: Alpha Particles; Animals; Antineoplastic Agents; Aspartic Acid; Bronchi; Cell Fusion; Cell Line, Tra | 1998 |
Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Topics: Animals; Aspartic Acid; Cells, Cultured; Female; Leukemia L1210; Lung Neoplasms; Mice; Mice, Inbred | 1979 |
Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Cells, Cult | 1978 |
Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Body Weight; Carbamates; Lung Neoplasms; Male; Mice; | 1977 |
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; D | 1976 |